EPIRETINAL MACROPHAGE-LIKE CELL ALTERATIONS FOLLOWING ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN BRANCH RETINAL VEIN OCCLUSION WITH MACULAR EDEMA
Anti-vascular endothelial growth factor therapy reduces macular eMLC in BRVO-ME patients, especially in early responders receiving three injections. Macular eMLCs are closely associated with inflammation and may serve as a valuable treatment response biomarker.
Authors
- Cheng Jian Sun (ORCID: https://orcid.org/0000-0003-0474-7593)
- Feng Wen (ORCID: https://orcid.org/0000-0003-3319-4051)
- Jin Yao (ORCID: https://orcid.org/0000-0001-9186-459X)
- Jiayi Li (ORCID: https://orcid.org/0000-0002-7770-7376)
- Yiyang Zhang (ORCID: https://orcid.org/0000-0001-6748-8272)
- Yue Zhao (ORCID: https://orcid.org/0000-0003-3800-5408)
- S. N. Zhu (ORCID: https://orcid.org/0000-0002-5693-5898)
- Wen L. Bai
Institutions
- Sun Yat-sen University (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Retina
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1097/iae.0000000000004723
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00